RNAZ Stock Summary and Trading Ideas (Transcode Therapeutics | NASDAQ:RNAZ)

TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.

Transcode Therapeutics trades on the NASDAQ stock market under the symbol RNAZ.

As of September 2, 2026, RNAZ stock price declined to $2.01 with 21,027 million shares trading.

RNAZ has a beta of 0.05, meaning it tends to be less sensitive to market movements. RNAZ has a correlation of 0.00 to the broad based SPY ETF.

RNAZ has a market cap of $2.13 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, RNAZ traded as high as $118,272.10 and as low as $1.83.

The top ETF exchange traded funds that RNAZ belongs to (by Net Assets): VXF.

RNAZ has underperformed the market in the last year with a price return of -79.3% while the SPY ETF gained +19.8%. RNAZ has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -63.0% and -38.0%, respectively, while the SPY returned +1.1% and -0.3%, respectively.

RNAZ support price is $1.86 and resistance is $2.26 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RNAZ shares will trade within this expected range on the day.